research papers high school sale dissertation in thesis essay literary online critical thinking skills for nurses pay some one to do my homework doctor of ministry thesis online expository research paper topics what makes a good college essay

Catalogue of Services

What do LS RIs offer the life science community?

 

The 13 European Life Science Research Infrastructures (LS RIs) have the mission to support cutting-edge science by offering access to their resources and services to European scientists from academia and industry.

Resources and services can simply be consultation, access to experts, but also access to data and biological samples, use of data analysis tools, access to facilities (e.g. highly specialised microscopes) plus support from technicians and much more.

Some of these services are even free to use for institutions location in the RI's member states. 

 

The Catalogue of Services, which has been developed within the CORBEL project, is the first tool to list the main services of all LS RIs at a glance and it aims to facilitate the utilisation of RI services by researchers from all over the world. The Catalogue of Services as displayed below aims to provide you a basic overview on existing services within distinct thematic fields.

 

You can either use the Catalogue of Services to identify a single RI to help you with your work or you can create a service pipeline, i.e. using several RIs simultaneously.

What’s your need?

Please select…

EATRIS-ERIC

Contact person(s): Anne-Charlotte Fauvel

EATRIS supports researchers in translating their findings into novel interventions including preventive, diagnostic or therapeutic products up to clinical proof of concept. The infrastructure comprises over 90 leading research institutions in the translational field located in 13 countries across Europe. EATRIS also supports the validation and development of novel tools for precision medicine and translational research in drug development. By providing access to accredited facilities as well as market-oriented expertise, including innovation management, regulatory and health-technology assessment, your validation needs are covered in a one-stop shop.

Services provided

Services offered by EATRIS include

  • support funding applications (Identification of partners for consortium building, assessment of the project plan's impact and innovation potential)
  • translational research facilities and expertise for development of novel biomarkers, diagnostics and therapeutics
  • molecular, functional & hybrid imaging technologies, preclinical models, samples, patient cohorts, GMP manufacturing
  • regulatory and Health Technology Assessment (HTA) expertise
  • advice on intellectual property issues and industry partnering strategy (innovation management)

Costs

Costs are calculated on a case by case basis depending on the service required; some services can also be provided as part of funding proposals with EATRIS joining consortia as partner or subcontractor.
For further information please contact us.

Access modes

Services performed can be offered either centrally by the coordination and support team based in Amsterdam or remotely by the EATRIS institutions.

Why work with us

Translating novel biology insights into effective interventions or medical applications is a highly complex process. It requires significant dedicated expertise, facilities and resources. We believe in your medical innovation and we want to support you by bringing together the multi-disciplinary expertise and infrastructure required for optimising your translational trajectory. Working with EATRIS gives greater confidence in the translational feasibility of your project and its impact.

Countries involved

FR, NL, CZ, SE, NO, FI, IT, ES, SI, LU, LV, PO, BG

Services contact

Contact person(s): Anne-Charlotte Fauvel

About

EATRIS, the European infrastructure for translational medicine, provides high quality services in early development of novel therapeutics and diagnostics. Translational research is defined as research that develops promising biomedical innovations 'from bench to bedside,' and conversely brings clinical insights from bedside back to bench.

Translational research is a highly multi-disciplinary and complex undertaking. As a consequence, a major challenge in developing new innovations is understanding what steps need to be taken, and what expertise and technologies are suitable to perform these steps. External researchers in need for academic support will find that EATRIS is able to provide guidance by means of regulatory, clinical and technological expertise available within the infrastructure. Subsequently, EATRIS will match the need with the capabilities within the infrastructure and facilitate collaboration among academics and between academics and companies.

Biomedical inventions frequently fail to pass the “valley of death” for various reasons. EATRIS aims to overcome translational challenges by (1) developing new enabling technologies within the consortium, and (2) making high quality services available for other researchers.

EATRIS strives to accelerate medicines and diagnostics development by utilising cutting-edge, enabling technologies in early translational research. Academic researchers, companies and charities can access clinical expertise and high-end facilities that are available within the 80 top-tier academic centres across Europe comprising EATRIS. Member institutions are selected on the basis of their track record in public-private collaboration in translational development and their multidisciplinary teams of leading academic experts, high-end research facilities, production laboratories and licenses.

We focus on preclinical and early clinical development of drugs, vaccines and diagnostics. Solutions are provided in the fields of advanced therapy medicinal products, biomarkers, imaging and tracing, small molecules and vaccines.

The wide-ranging services portfolio focuses on supporting early decision-making and de-risking of projects. Examples include validation and development of in vitro and in vivo biomarkers for patient stratification, molecular imaging tracers for drug development programmes, GMP manufacturing of cellular therapy products, patient-derived xenograft models, and many more highly specialised capabilities.

General contact

Website: eatris.eu

Contact person(s): Anton Ussi

ERINHA

Contact person(s): Dr. Hervé Raoul, Diana Stepanyan-Yerdamian, contact(at)erinha.eu

ERINHA is a pan-European distributed life sciences research Infrastructure dedicated to the study of highly infectious emerging and re-emerging high-consequence pathogens (RG4 & unknown). It brings together leading European high containment and complementary research facilities and expertise required to perform cutting-edge research on highly infectious diseases. ERINHA provides access to its state of art BSL-4 laboratories and complementary capacities and expertise to perform excellence orientated in-vitro and in-vivo research projects, trainings and advise. A wide range of capabilities and functions from high basic research laboratory capacities to NHP modeling research are provided by ERINHA, as well as expertise of senior scientists and access to complementary functions (from BSL1 to BSL4, genomics, proteomics etc.).

 

ERINHA produces the ideal environment to facilitate coordination of research on high-consequence pathogens in Europe. The infrastructure will contribute to the enhancement of the European and global capacity, capability and emergency preparedness in the response to global outbreaks.

 

Since 2018, ERINHA has been granted landmark status by the European Strategy Forum on Research Infrastructures (ESFRI).

 

Services provided

The services offered by ERINHA include

  • Access to state of art European high containment (BSL4 & BSL3) and complementary facilities to advance research on high-consequence pathogens. In-vivo testing with a variety of animal models (including small rodents, ferrets, and non-human primates). In-vitro experiments using highly pathogenic agents with both in-person and remote access possibilities.
  • Project coordination and management of large scale research programmes on high consequence pathogens
  • Training (General Biosecurity Training; Operations of a Biosafety Laboratory; Training for potential users)
  • Advice and scientific expertise provider: RG4 pathogens research, containment facilities construction, biosafety/biosecurity issues, sample transport etc.
  • Access to pathogens specimens

Costs

For access costs information contact ERINHA Central Coordinating Unit (CCU) at contact(at)erinha.eu

Access modes

ERINHA provides in-person and remote access to its services. Projects can be submitted by academic, public and industrial users. For more information contact ERINHA CCU at contact(at)erinha.eu

Why work with us

The 2014-2015 Ebola outbreak and cases in Europe demonstrated the worldwide vulnerability and need for common action putting together rare high containment capacities and expertise to be able to increase European and global preparedness for outbreaks of high consequence pathogens. ERINHA facilitates access to required infrastructure capacities thanks to its CCU and multiple high containment and complementary European resources. It is a unique coordinated infrastrucuture providing transnational access to its facilities, large scope of services and shorter delays in access.

Countries involved

France (Inserm), Portugal (INSA), Sweden (FOHM), Hungary (Ministry of Human Capacities), Netherlands (ERASMUS MC), Belgium (KUL)

Services contact

Contact person(s): Dr. Hervé Raoul, Diana Stepanyan-Yerdamian, contact(at)erinha.eu

About

ERINHA is a pan-European distributed life sciences research Infrastructure dedicated to the study of highly infectious emerging and re-emerging high-consequence pathogens (RG4 & unknown). It brings together leading European high containment and complementary research facilities and expertise required to perform cutting-edge research on highly infectious diseases. ERINHA provides access to its state of art BSL-4 laboratories and complementary capacities and expertise to perform excellence orientated in-vitro and in-vivo research projects, trainings and advise. A wide range of capabilities and functions from high basic research laboratory capacities to NHP modeling research are provided by ERINHA, as well as expertise of senior scientists and access to complementary functions (from BSL1 to BSL4, genomics, proteomics etc.). 

ERINHA produces the ideal environment to facilitate coordination of research on high-consequence pathogens in Europe. The infrastructure will contribute to the enhancement of the European and global capacity, capability and emergency preparedness in the response to global outbreaks.

Since 2018, ERINHA has been granted landmark status by the European Strategy Forum on Research Infrastructures (ESFRI).

General contact

Website: www.erinha.eu

Contact person(s): Dr. Hervé Raoul, contact(at)erinha.eu

EU-OPENSCREEN

Contact person(s): Project Manager: Dr. Tanja Miletic

EU-OPENSCREEN integrates high-capacity screening platforms throughout Europe, which jointly use a rationally selected compound collection, comprising up to 140.000 commercial and proprietary compounds collected from European chemists. EU-OPENSCREEN offers to researchers from academic institutions, SMEs and industrial organisations open access to its shared resources.

EU-OPENSCREEN will collaboratively develop novel molecular tool compounds with external users from various disciplines of the life sciences.

Services provided

Services provided by EU-OPENSCREEN include

  • high-throughput compound/ drug screening (HTS): HTS of an assay against the EU-OPENSCREEN chemical collection (> 100,000 compounds); in silico profiling; hit selection; confirmatory screening; basic counter screening; basic SAR based on screening data; QC of confirmed hits
  • access to a unique European compound collection: EU-OPENSCREEN chemical collection (> 100,000 compounds)
  • assay adaption: This assay adaptation process will involve a strong emphasis on quality, including: quality control of reagents; (patho-)physiological relevance; pharmacological consistency; robustness; minimised variability; and tracking of statistical descriptors (e.g. signal to background and the Z’ factor) 
  • chemical optimization and profiling of preliminary ‘hits’
  • bioprofiling of donated compounds: All compounds donated by the user which enter the EU-OPENSCREEN ERIC compound collection are characterised and annotated for basic physico-chemical (e.g. identity, solubility, light absorbance and fluorescence) and essential to know biological properties (cytotoxicity, antibiotic, antifungal etc.) by testing in a standard panel of assays.
  • provision of standardised data: All data generated through QC/bioprofiling and screening activities will be published in EU-OPENSCREEN’s open-access database with an optional ‘grace’ period (i.e. delayed publication of data). Large-scale open-access data provide the basis for computational data integration to obtain a systematic view, allow for prediction of drug-target interactions and networks as well as of adverse effects and drug combinations. The access to the EU-OPENSCREEN database will utilize the facilities of ChEMBL.
  • training and education activities

Costs

A screening project at a typical EU-OPENSCREEN screening site will cost 50-250k €, strongly depending on the number of screened substances and the maturity/ complexity of the assay.
A compound replenishment fee structure applies to all projects using the EU-OPENSCREEN compound collection and users from countries which are members of the EU-OPENSCREEN ERIC will receive a discount on this cost.
For further information please contact us.

Access modes

Users are requested to submit project proposal to the EU-OPENSCREEN office. Depending on the project requirements, the RI can be assessed remotely or on-site.

Why work with us

The majority of scientists in Europe do not have access to suitable technology platforms and compound collections, which are generally expensive to purchase, operate and maintain. As a large-scale research infrastructure (RI) with an ‘open’ pre-competitive character, EU-OPENSCREEN will cost-effectively overcome this limitation by: involving and providing access to Europe’s leading screening platforms and chemistry groups; offering a jointly used rationally designed compound collection; and operating an open-access bioactivity database which will be accessible on a global basis. EU-OPENSCREEN offers to support you through grant application processes and beyond for funding involving screening projects.

Countries involved

CZ, FI, DE, LV, NO, PO, ES, DK

Services contact

Contact person(s): Project Manager: Dr. Tanja Miletic

About

Chemical Biology is a new interdisciplinary research field which studies the effects of chemical compounds on biological systems. The primary objective of EU-OPENSCREEN is to offer access to a distributed Chemical Biology research infrastructure which meets the needs of scientists seeking a better understanding on how fundamental molecular processes act to govern biological function at the organismal, tissue, cellular and pathway levels by applying small chemical compounds.

Using a well-founded collaborative working model, infrastructure users and EU-OPENSCREEN teams will identify and develop novel small chemical compounds which elicit specific biological responses on organisms, cells or cellular components. These bioactive compounds are identified by means of screening large collections of >100,000 molecules, in an automated process, using robotics-based high-throughput screening platforms, and optimised by medicinal chemistry means.

The majority of scientists in Europe, however, do not have access to suitable technology platforms and compound collections, which are generally expensive to purchase, operate and maintain. As a large-scale research infrastructure (RI) with an ‘open’ pre-competitive character, EU-OPENSCREEN will cost-effectively overcome this limitation by: involving and providing access to Europe’s leading screening platforms and chemistry groups; constructing a jointly used compound collection; and operating an open-access bioactivity database which will be accessible on a global basis.

The chemical compounds which will be developed in the framework of EU-OPENSCREEN have a number of key advantages and allow interrogation of complex biological processes that cannot be properly studied with traditional genetic approaches. They drive innovation as they help validate biological targets as ‘druggable’ (i.e. be modulated by chemical compounds) which makes them highly attractive starting points for further optimisation into marketable medicines or crop-protective agents by pharmaceutical, AgriScience and biotechnology companies.  

Access to the EU-OPENSCREEN expertise and resources is available to all researchers worldwide. EU-OPENSCREEN will represent a globally relevant resource and will attract users from a variety of scientific disciplines and geographical regions. The key users can be divided into three major user groups:

  1. Assay providing users who will access the screening infrastructure: Researchers with a suitable, robust and screening compatible assay, interested in developing specific chemical compounds (i.e. inhibitor or activator) for their biological mechanism or pathway-of-interest to answer a biological question. In the first step, these assays are screened against the EU-OPENSCREEN ERIC compound collection; in the second step, the identified active compounds (‘hits’) are chemically optimised and translated into valuable tool compounds, which are made available to the broader scientific community.
  2. Compound providing users who will donate compounds: Chemists who donate their compounds can use the EU-OPENSCREEN services to expose their compounds to a large number of screens, and thereby a wide range of biological targets. The unique value proposition for chemists is that the biological activities of their compounds will be described in-depth and that their compounds may be identified as active 'hit' compounds, thereby triggering new collaborations between chemistry and biology communities.
  3. Database users who will access the EU-OPENSCREEN database: The open-access EU-OPENSCREEN database will serve as the publicly accessible database and collaborative data sharing environment for all EU-OPENSCREEN generated data. It is designed to support the requirements of both academia (encouraging exchange of knowledge) and industry (allowing suitable protection of IP).

General contact

Website: www.eu-openscreen.eu

Contact person(s): office(at)eu-openscreen.eu

Please note: Most of the RIs are constantly developing their portfolio of services, so if you do not find the service/tool you are looking for, do not hesitate to contact the RI and ask for it!

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 654248.